Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. The conversation questions the effectiveness and patience required for these treatments.
The conversation discusses the experience of hair shedding after starting sublingual oral Minoxidil, with the user questioning whether to continue the treatment. Responses suggest persisting with the treatment as shedding might lead to positive results.
The conversation discusses the safety and effectiveness of continuing or adding RU58841 after stopping finasteride for hair loss treatment. One user expresses skepticism about using RU58841 due to the lack of full human trials.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.
The user reports progress in hair regrowth using topical finasteride/minoxidil, microneedling, topical dutasteride, latanoprost, and MSM supplements. They express frustration over the lack of interaction on progress posts compared to trivial topics.
The user shared progress pictures showing improvement in hair loss after 4 months of using Minoxidil and plans to start Finasteride. They received advice to stay consistent and consider oral Minoxidil.
The conversation discusses hair regrowth using oral minoxidil and RU58841, with visible baby hairs appearing after two months. One user questions the choice of RU58841 over finasteride.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.